Twin Power for Total Control



Linagliptin 5mg


  • Type 2 Diabetes Mellitus (T2DM) Management
  • DPP-4 Inhibitor
  • Blood Sugar Control
  • Treatment Limitations
  • Prescription-Based Usage



  • An effective once-daily treatment option in patients with T2D and severe renal impairment
  • Primarily eliminated via the enterohepatic system thus no dose adjustment is needed in patients with kidney impairment as compared to sitagliptin, saxagliptin, and vildagliptin
  •  Well tolerated with a low risk of hypoglycemia
  •  Significant and sustained improvement in glycemic. control in patients with T2D and restore B-cell functions. Cretetes Obes letab 2001111254-207
  •  Attenuates postprandial glucose levels and, with significant reductions in HbA1c after only 4 weeks of treatment.
  •  Exhibits superior glucose-lowering efficacy and comparable safety and tolerability to Voglibose in patients with T2DM